On March 13, 2013, leaders from JHL Biotech and GE Healthcare Life Sciences signed a strategic cooperation agreement. The two companies will build a monoclonal antibody manufacturing plant in Wuhan’s Biolake Science Park. Many executives from Biolake participated, including Deputy Director of East Lake High-Tech Zone, Director of Biological Department, Changchun Dan and Biological department leaders Zhongyu Yan and Yunhua Yuan.
MabVax Therapeutics has received a contract from the National Cancer Institute under the Small Business Innovation Research Technology Program (SBIR). The award is in the amount of $1,750,000 over the next three years and will support development of a novel positron emission tomography (PET)imaging product for the diagnosis, staging, and treatment assessment of pancreatic cancer.
WhiteGlove Health, (WGH) a leading service driven and outcomes-oriented healthcare provider, focusing on enhancing quality and improving the consumers’ healthcare experience while lowering the cost, today announced the appointment of Nicholas A. Balog, MPH as Chief Executive Officer. He will be responsible for leading the organization and advancing the company’s strategic vision while ensuring excellence in its service delivery.
On March 13, 2013, leaders from JHL Biotech and GE Healthcare Life Sciences signed a strategic cooperation agreement. The two companies will build a monoclonal antibody manufacturing plant in Wuhan’s Biolake Science Park. Many executives from Biolake participated, including Deputy Director of East Lake High-Tech Zone, Director of Biological Department, Changchun Dan and Biological department leaders Zhongyu Yan and Yunhua Yuan.
Cordis Corporation, a worldwide leader in the development of interventional vascular technology, today announced it has completed the acquisition of Flexible Stenting Solutions, Inc., a leading developer of innovative flexible peripheral arterial, venous and biliary stents.
Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells (product name: LG631-CD34) for bone marrow protection in the treatment of glioblastoma multiforme. Orphan drug designation qualifies Lentigen for seven years of market exclusivity following marketing approval by the FDA and provides other development-related incentives.
The proceeds of the financing of the Series B is to accelerate the growth of the company's evolution into precision diagnostics in healthcare and expand Strand's reach into global markets. Strand will leverage its expertise in genomics and analytics that it has developed over a decade. In taking its technology platforms from bench to bedside, Strand is uniquely positioned to bring the power of high precision genomic measurement methods such a Next Generation Sequencing (NGS) to applications in screening and identification of diseases with genetic-basis and in precisely classifying cancer types to personalize therapy and care.
MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of proprietary immunotherapies to address the unmet medical need of preventing recurrent cancer, today announced the closing of the first tranche in their Series B financing. Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of $5.25 million. The additional capital will allow MabVax to continue the development of its phase 2 vaccine aimed at preventing recurrent sarcoma and its 5B1 antibody program targeting metastatic pancreatic cancer.
University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar.